Dialysis Geriatric Care Model
Integration of Geriatric Care Into Dialysis Clinics
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Megan A Reaves, MS
- Phone Number: 9196602272
- Email: megan.reaves@duke.edu
Study Contact Backup
- Name: Rasheeda K Hall, MD, MBA, MHS, FASN
- Phone Number: 9196606861
- Email: rasheeda.hall@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Patient Inclusion Criteria:
- community-dwelling dialysis patients 55 and older
- may have cognitive impairment
Patient Exclusion Criteria:
- advanced dementia
- non-English or Spanish speaking
- nursing home residents
- hospice enrollees
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Usual Care
Participants will receive usual dialysis care for 12 months, then they will receive the geriatric care model.
|
Participants will continue to receive standard of care.
Then after 12 months, they will follow the Geriatric Care Model.
They will complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems.
Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
|
|
Active Comparator: Geriatric Care Model
Participants will complete the GOLD, along with a few additional short surveys and a Short Physical Performance Battery.
Information gathered will guide the research geriatric team's recommendation report to the participants' dialysis care team.
The dialysis teams will receive training on how to use the recommendation report and local resources to initiate geriatric problem management.
Participants will be seen every 4 months for follow-up for roughly 12 months.
|
First, older adults complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems.
Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in geriatric problem management as measured by survey
Time Frame: Baseline, 4 months
|
Problems include depression, anxiety, difficulty with memory, difficulty with daily activities, falling or fear of falling, obtaining and following instructions for taking medications, having unwelcome side effects from medications, not having enough support from others, and not having access to or eating enough food.
The score for each problem ranges from 0 to 4, where a higher score indicates better management of the problem.
|
Baseline, 4 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Practicality as measured by amount of time utilized by study personnel to conduct RCT (randomized controlled trial)
Time Frame: up to 12 months
|
up to 12 months
|
|
|
Retention as measured by number of participants who complete the study
Time Frame: up to 12 months
|
up to 12 months
|
|
|
Recruitment as measured by number of participants enrolled
Time Frame: up to 12 months
|
up to 12 months
|
|
|
Practicality as measured by number of participants who needed study personnel assistance to complete the GOLD electronically
Time Frame: up to 12 months
|
up to 12 months
|
|
|
Fidelity as measured by the Care model recommendation checklist
Time Frame: Baseline, 4 months
|
Care model recommendation checklist includes a recommendation informed by the GOLD, recommendation align with patient priority, recommendation received by clinician, and recommendation decision
|
Baseline, 4 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Rasheeda K Hall, MD, MBA, MHS, FASN, Duke University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Renal Insufficiency
- Pathological Conditions, Signs and Symptoms
- Renal Insufficiency, Chronic
Other Study ID Numbers
Other Study ID Numbers
- Pro00112850
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.